Since AR is the key driver pathway of prostate cancer development, it is not surprising that the most consistent efforts in the development of new therapies consisted in identification and clinical study of new agents blocking AR, suitable for the treatment of patients during the stages of androgen dependency and independency of the disease. The gene discussed is AR; the disease is prostate carcinoma.